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Abstract
Background: Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors.
Previous studies have demonstrated lower serum BDNF levels in patients with major depressive disorder (MDD) and
reported an association between BDNF levels and depression-related personality traits in healthy subjects. The aim
of the present study was to explore for a possible association between peripheral BDNF levels and personality traits
in patients with MDD.
Methods: In this cross-sectional study, a total of 123 inpatients with MDD (Diagnostic and Statistical Manual for Mental
Disorders, 4th edition) at the Juntendo University Koshigaya Hospital were recruited. Serum levels of BDNF were
measured. Personality traits were assessed using the 125-item short version of the Temperament and Character
Inventory (TCI).
Results: Multiple regression analysis adjusted for age, sex, body mass index, dose of antidepressant, and depression
severity showed that TCI Self-Directedness (SD) scores were negatively associated with serum BDNF levels (β = −0.23,
p = 0.026).
Conclusions: MDD patients who have low SD did not show the reduction in serum BDNF levels that is normally
associated with depressive state. Our findings suggest that depression-related biological changes may not occur in
these individuals.
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Background
Brain-derived neurotrophic factor (BDNF) is a member
of the neurotrophin family of growth factors, which also
includes nerve growth factor, neurotrophin-3, and
neurotrophin-4/5 [1]. BDNF is the most abundant neu-
rotrophin in the brain, playing a critical role in growth,
differentiation, maintenance, and synaptic plasticity. Ani-
mal models demonstrate a stress-induced dysregulation
of BDNF expression, especially in response to chronic
stress [2]. In humans, lower serum BDNF levels have
been found in patients with major depressive disorder
(MDD) [3,4], bipolar disorder [5,6], schizophrenia [7,8],
eating disorders [9,10], obsessive-compulsive disorder
[11], and alcohol dependence [12]. In most studies in-
volving MDD, serum BDNF levels have been shown to
correlate negatively with disease severity [13-15], and
antidepressant treatment increases serum levels of
BDNF [14,16-19]. However, there is a large overlap bet-
ween BDNF levels in the serum of depressed patients
and controls [15], and levels are not decreased in all de-
pressed patients.
The Temperament and Character Inventory (TCI) is
based on a psychobiological model that describes the
structure and development of personality with four tem-
perament and three character dimensions. In this psy-
chobiological model, Cloninger et al. [20] postulated that
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temperament is genetically independent, emerges in
early life, and influences subsequent perceptual memory
and habit formation. In addition, they propose that
character is determined by learning about self-concepts,
matures in adulthood, and affects personal and social
lives over time. The temperament dimensions of the
TCI consist of Novelty-Seeking (NS), Harm-Avoidance
(HA), Reward-Dependence (RD), and Persistence (P).
The three character dimensions are Self-Directedness
(SD), Cooperativeness (C), and Self-Transcendence (ST).
A number of studies using the TCI suggest that de-
pressed patients show high HA and low SD, and these
personality traits are associated with the state of depres-
sion [21-28]. Hansenne et al. [24] administered the TCI
to 40 patients with MDD and 40 healthy controls. De-
pressed patients exhibited higher HA and ST scores as
well as lower SD and C scores compared to controls.
The three other dimensions did not differ between de-
pressed patients and controls. Among the depressed
group, HA, SD and C dimensions were related to the se-
verity of depression as assessed by the Hamilton Rating
Scale for Depression (HAM-D). Kimura et al. [21] mea-
sured personality traits in 131 remitted patients with
MDD and 154 normal controls. Patients with MDD had
significantly higher HA scores and significantly lower
SD and C scores. Hirano et al. [27] evaluated 108 pa-
tients with MDD using the TCI before and after a 16-
week antidepressant treatment. The level of depression,
as assessed by HAM-D, was correlated positively with
the HA score and negatively with the SD and C scores.
Moreover, treatment both reduced the severity of de-
pression and normalized scores on these three dimen-
sions. More recently, Celikel et al. [26] used the TCI in
81 outpatients (67 women, 14 men) and 51 healthy con-
trols (35 women, 16 men). Depressed patients exhibited
significantly higher HA scores and lower SD scores com-
pared with healthy controls. Hur et al. [28] also exa-
mined 56 patients with MDD and the same number of
age-, sex-, and education-matched normal controls using
the TCI. MDD patients had significantly higher HA
scores and significantly lower scores for SD and C and
subscales of NS, RD, and ST than normal controls.
Kaneda et al. [25] measured TCI in 93 patients with
MDD before and after 6 weeks of selective serotonin re-
uptake inhibitor (SSRI) treatment. Compared with 91
normal control participants, patients with MDD had less
NS and SD and greater HA. Moreover, they found early
treatment responders showed less HA and more SD
than late responders. Kampman et al. [23] measured
traits using the TCI in 98 patients with MDD before and
after 6 weeks of SSRI treatment. MDD patients had sig-
nificantly higher HA scores compared with community
samples both at baseline and endpoint, and HA was the
trait that accounted for the most variability in the post-
treatment Montgomery Asberg Depression Rating Scale
(MADRS) scores. The authors concluded that HA was
associated with the risk of and treatment response to de-
pression. A recent systematic review and meta-analysis
[22] demonstrated that high HA was associated with
current depressive symptoms and with depressive trait.
These previous reports suggest that HA and SD scores
with depression are more consistently associated with
depression than other dimensions of TCI. The HA score
quantifies the extent to which a person is anxious, pes-
simistic, and shy or risk-taking, optimistic, and outgoing.
The SD score quantifies executive functions, such as
responsibleness, purposefulness, and resourcefulness. A
high HA score indicates that a person is anxiety prone,
which may create an emotional venerability to depres-
sion [29]. A high SD score indicates that an individual
may lack executive functions that protect a person from
depression, and a low SD score indicates immature per-
sonality [29].
Previous reports have only examined the relationships
between blood BDNF levels and personality traits in
healthy subjects [30-34]. These studies demonstrated
an association between peripheral BDNF levels and
depression-related personality traits. To our knowledge,
however, no study has examined the relationship be-
tween peripheral BDNF levels and personality traits in
patients with MDD. While serum BDNF levels are nega-
tively correlated with depressive symptoms, not all de-
pressed patients display lower serum BDNF levels than
controls [15]. We hypothesize that serum BDNF levels
do not decrease in MDD patients with high HA or low
SD because these traits may enhance susceptibility to
depression even in the absence of biological changes.
The aim of the present study was to explore the possible
association between peripheral BDNF levels and person-
ality traits evaluated by the TCI in patients with MDD.
Thus, we analyzed the association between HA and SD
scores and serum BDNF levels. This study is a part of
the Juntendo University Mood Disorder Project (JUMP).
Methods
Subjects
In this cross-sectional study, a total of 123 inpatients
with who met the Diagnostic and Statistical Manual
for Mental Disorders, 4th edition (DSM-IV) criteria
for MDD were recruited from the Juntendo Koshigaya
Hospital between May 2006 and December 2013. The
diagnosis was done by senior psychiatrists. Exclusion cri-
teria included history of other psychiatric disorders
including delusions, severe or acute medical illnesses,
neurological disorders, use of drugs that may cause de-
pression, clinical evidence of dementia, and Mini-Mental
State Examination scores <24. Psychotic symptoms were
present in 19 patients. Twenty-five patients were smokers.
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With regard to chronic physical problems, 20 patients had
hypertension (HT), 11 patients had hyperlipidemia (HL),
and eight patients had diabetes mellitus (DM). Depressive
symptoms were assessed using the HAM-D [35] on ad-
mission to the hospital. All patients were on antidepres-
sant medication but were not responding to their current
medication. The antidepressant doses were converted to
equivalent doses of imipramine [36]. Numbers of depres-
sive episodes were confirmed via medical records.
All study protocols were approved by the Medical
Ethics Committee of Juntendo University Koshigaya
Hospital and were performed in accordance with the
regulations outlined by Juntendo University. All par-
ticipants provided written informed consent prior to
participation.
Assessment of personality traits
Personality traits were assessed using the 125-item short
version of TCI [37]. Reliability and validity of the Japanese
version in a nonclinical population [37] and factor validity
in outpatients with major depression [38] have been
reported.
The temperament dimensions of the TCI measure in-
dividual differences in emotional responses to associa-
tively conditioned stimuli. The four temperaments are
HA (i.e., anxious versus risk-taking), NS (i.e., impulsive
versus rigid), RD (i.e., approval seeking versus aloof ),
and P (i.e., overachieving versus underachieving). The
character dimensions measure individual differences in
higher cognitive processes that modulate emotional con-
flicts to satisfy a person’s goals and values. The character
dimensions quantify the three branches of mental self-
government: SD (executive functions, such as being
responsible, purposeful, and resourceful), C (legislative
functions, such as being tolerant, forgiving, and helpful),
and ST (judicial functions, such as being intuitive, judi-
cious, and aware) [29].
Serum BDNF measurements
Blood samples were taken at 07:00, before breakfast, on
the day after admission and were centrifuged imme-
diately after blood was drawn and clotting confirmed.
Serum samples were stored at -80°C until the time of
processing. A Quantikine Human BDNF Immunoassay
Kit (R&D Systems, Minneapolis, MN, USA) was used
according to the instructions from the manufacturer
and as previously described [33]. The detection limit
was 20 pg/ml and the intra-assay coefficient of variation
was <8%.
Statistical analysis
Correlations between serum BDNF levels, HA or SD
scores, and possible confounding factors (age, sex, daily
dose of antidepressants, HAM-D total score, presence of
psychotic symptoms, age of onset, education, smoking,
presence of HT, HL, DM, and body mass index [BMI])
were analyzed using Spearman’s rank correlation co-
efficient. Multiple regression analysis was conducted
using serum BDNF levels as a dependent variable and
confounding factors, HA score, and SD score as inde-
pendent variables. The significance level was p < 0.05.
Statistical procedures were performed using the Japanese
version of SPSS v15.1 (SPSS Inc., Japan, Tokyo, Japan).
Results
Participants (N = 123) included 44 men and 79 women with
a mean age of 56.8 years (range, 31–85 years). Participant
characteristics are shown in Table 1. Serum BDNF levels
were negatively correlated with age (R = −0.38, p < 0.001)
and age of onset (R = −0.26, p = 0.003) and positively corre-
lated with sex (R = 0.24, p = 0.009), daily dose of antidepres-
sants (R = 0.26, p = 0.008), and BMI (R = 0.30, p = 0.001).
Correlations between serum BDNF levels and other pos-
sible confounding factors were not significant. HA score
was negatively correlated with age (R = −0.24, p = 0.008)
and age of onset (R = −0.18, p = 0.04) and was not
correlate with other possible confounding factors. No
correlations between SD score and confounding factors




Age (years old) 56.8 ± 14.1
Sex (F/M) 79/44
Education (years) 13.0 ± 2.6
BMI (%) 23.0 ± 3.5
Age of onset (years old) 49.9 ± 15.8
HAM-D total score 22.0 ± 9.8
Number of depressive episodes 2.0 ± 1.2
Duration of current episode (months) 11.9 ± 13.2
Daily dose of antidepressant (mg)a 129.5 ± 98.3
Novelty-Seeking (NS) 7.7 ± 2.8
Harm-Avoidance (HA) 13.9 ± 4.1
Reward-Dependence (RD) 9.2 ± 2.5
Persistence (P) 2.2 ± 1.6
Self-Directedness (SD) 14.6 ± 5.1
Cooperativeness (C) 16.6 ± 3.4
Self-Transcendence (ST) 3.9 ± 2.9
Serum BDNF level (pg/ml) 19283.9 ± 7952.6
aAntidepressants were converted into equivalent doses of imipramine.
MDD, major depressive disorder; SD, standard deviation; F, female; M, male;
BMI, body mass index; HAM-D, Hamilton Rating Scale for Depression;
BDNF, brain-derived neurotrophic factor.
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were significant. There was a strong, positive correlation
between age of onset and age. From these results, we as-
sumed age, sex, BMI, daily dose of antidepressants, and
HAM-D score as significant confounding factors.
Multiple regression analysis showed that age (β = −0.38,
p < 0.001) and SD score (β = −0.23, p = 0.026) were signifi-
cantly associated with serum BDNF levels after controlling
for HAM-D total score and other confounding factors.
Sex, HAM-D total score at admission, daily dose of anti-
depressants, BMI, and HA score were not significantly as-
sociated with serum BDNF levels (Table 2).
Discussion
The present study demonstrated that there was an
inverse relationship between serum BDNF levels and
scores for the SD personality trait in patients with MDD.
In terms of the association between peripheral BDNF
levels and personality traits, Lang et al. [30] reported a
negative correlation between serum BDNF levels and
neuroticism in 118 healthy subjects, evaluated by the
Neuroticism-Extroversion-Openness (NEO) Five-Factor
Inventory. Terracciano et al. [39] reported that serum
BDNF levels were inversely related to neuroticism, mea-
sured by the Revised NEO Personality Inventory in a
large community-based study (n = 2099). This associa-
tion of serum BDNF levels with neuroticism was in-
dependent of depressive symptoms. Okuno et al. [32]
reported a positive correlation between plasma BDNF
levels and the extroversion score measured by the NEO
Five-Factor Inventory in 269 healthy employees. Other
studies have evaluated personality traits using the TCI.
Minelli et al. [33] reported a negative correlation bet-
ween HA scores and serum BDNF levels in 107 healthy
subjects. Yasui-Furukori et al. [34] also reported that
plasma BDNF levels were negatively correlated with HA
scores and positively correlated with SD scores in 178
healthy subjects. Inconsistent with results of these pre-
vious studies [33,34], we found that serum BDNF levels
were not correlated with HA scores and were negatively
correlated with SD scores in patients with MDD. How-
ever, these previous studies were performed in healthy
subjects. To our knowledge, this article is the first to re-
port an association between serum BDNF levels and per-
sonality traits in patients with MDD. The discrepancy in
these results may be caused by the differences in diagno-
sis of subjects.
Previous studies have demonstrated lower serum
BDNF levels in depressed patients than in controls
[13,16,40]. Similarly, we previously found lower serum
BDNF levels in 109 patients with MDD compared with
163 healthy controls [15]. From these previous studies,
serum BDNF levels may reflect a depression-related
biological change. However, we found a large overlap in
patients with MDD and controls (mean levels and stan-
dard deviations were 20,321.2 ± 8180.0 pg/ml in MDD
patients and 27,105.5 ± 8310.2 pg/ml in controls), and
there were patients with MDD whose serum BDNF levels
were not lower than the control mean. In the present
study, we hypothesized that the variability in serum BDNF
levels was due to an absence of depression-related bio-
logical changes in MDD patients with weak SD, and this
hypothesis was supported by the negative correlation bet-
ween serum BDNF and SD. Previous studies suggest that
SD is a marker of executive functions that protect a per-
son from depression, and low SD scores indicate immatu-
rity [29]. Individuals with low SD may be more likely to
fall into a depressive state when experiencing undesirable,
though not overtly stressful, situations in daily lives. Thus,
biological changes caused by strong and continuous stress
may be less likely to occur in MDD patients with low SD
personality trait. In summary, the depressive state in
MDD patients with low SD personality trait may be af-
fected more by psychological than biological factors.
A key limitation of the present study was that all pa-
tients with MDD were on antidepressant medications.
However, serum BDNF levels were not influenced by the
type (data not shown) or dose (Table 2) of antidepres-
sant. Yoshimura et al. [19] found that paroxetine and
milnacipran increased serum BDNF levels to similar
levels in responders. Serum BDNF levels may change
only with successful medication [19], and our patients
were not responsive to the medications they were re-
ceiving at the time of the study. Although we did not
find a significant association between antidepressants
and BDNF levels, follow-up studies in drug-naïve pa-
tients should be conducted. Genetic considerations
were beyond the scope of this study, but future work
should explore the VAL/MET polymorphism of the
BDNF gene as a biomarker. Additional limitations of
this study include small sample size and an exclusion of
other personality traits besides SD and HA. Future stu-
dies should explore a wider array of personality traits
using larger samples.





HAM-D total score at admission 0.03 0.774
Daily dose of antidepressant 0.12 0.199
BMI 0.08 0.429
Harm-Avoidance (HA) -0.05 0.613
Self-Directedness (SD) -0.23 0.026
BDNF, brain-derived neurotrophic factor; HAM-D, Hamilton Rating Scale for
Depression, BMI, body mass index.
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Conclusions
Serum BDNF levels are negatively associated with the
personality trait of SD in patients with MDD. While
most patients with MDD have reduced serum BDNF
levels, the patients with lower SD showed higher serum
BDNF levels than other patients with MDD, suggesting
that a depressive state is not linked with depression-
related biological changes in these patients.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NH and HB conceived of the study, designed the study, conducted the
statistical analysis, interpreted the data, and wrote the initial draft of the
manuscript. ES and HM carried out the statistical analysis and interpreted the
data. NT and YT recruited participants and collected data. TS and HA
conceived of the study and participated in its design and coordination.
All authors read and approved the final manuscript. HN and HB contributed
equally to this work.
Acknowledgments
This work was supported by grants from the Research Support Foundation
of the Juntendo Institute of Mental Health.
Received: 1 August 2014 Accepted: 19 February 2015
References
1. Hallbook F, Ibanez CF, Persson H. Evolutionary studies of the nerve growth
factor family reveal a novel member abundantly expressed in Xenopus
ovary. Neuron. 1991;6(5):845–58.
2. Nowacka M, Obuchowicz E. BDNF and VEGF in the pathogenesis of
stress-induced affective diseases: an insight from experimental studies.
Pharmacol Rep. 2013;65(3):535–46.
3. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood
disorders. Biol Psychiatry. 2006;59(12):1116–27.
4. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG,
Placentino A, et al. Serum and plasma BDNF levels in major depression:
a replication study and meta-analyses. World J Biol. 2010;11(6):763–73.
5. de Oliveira GS, Cereser KM, Fernandes BS, Kauer-Sant’Anna M, Fries GR,
Stertz L, et al. Decreased brain-derived neurotrophic factor in medicated
and drug-free bipolar patients. J Psychiatr Res. 2009;43(14):1171–4.
6. Fernandes BS, Gama CS, Kauer-Sant’Anna M, Lobato MI, Belmonte-de-Abreu P,
Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and
unipolar depression: a potential adjunctive tool for differential diagnosis.
J Psychiatr Res. 2009;43(15):1200–4.
7. Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A,
Vasilopoulos D, et al. Reduced serum BDNF levels in patients with chronic
schizophrenic disorder in relapse, who were treated with typical or atypical
antipsychotics. World J Biol Psychiatry. 2010;11(2-2):251–5.
8. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum
brain-derived neurotrophic factor a biomarker for cognitive enhancement in
schizophrenia? Biol Psychiatry. 2009;66(6):549–53.
9. Nakazato M, Hashimoto K, Shimizu E, Kumakiri C, Koizumi H, Okamura N,
et al. Decreased levels of serum brain-derived neurotrophic factor in female
patients with eating disorders. Biol Psychiatry. 2003;54(4):485–90.
10. Saito S, Watanabe K, Hashimoto E, Saito T. Low serum BDNF and food
intake regulation: a possible new explanation of the pathophysiology
of eating disorders. Prog Neuropsychopharmacol Biol Psychiatry.
2009;33(2):312–6.
11. Maina G, Rosso G, Zanardini R, Bogetto F, Gennarelli M, Bocchio-Chiavetto L.
Serum levels of brain-derived neurotrophic factor in drug-naive obsessive-
compulsive patients: a case-control study. J Affect Disord. 2010;122(1–2):174–8.
12. Zanardini R, Fontana A, Pagano R, Mazzaro E, Bergamasco F, Romagnosi G,
et al. Alterations of brain-derived neurotrophic factor serum levels in
patients with alcohol dependence. Alcohol Clin Exp Res. 2011;35(8):1529–33.
13. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased
serum brain-derived neurotrophic factor levels in major depressed patients.
Psychiatry Res. 2002;109(2):143–8.
14. Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, et al.
Partial normalization of serum brain-derived neurotrophic factor in
remitted patients after a major depressive episode. Neuropsychobiology.
2005;51(4):234–8.
15. Satomura E, Baba H, Nakano Y, Maeshima H, Suzuki T, Arai H. Correlations
between brain-derived neurotrophic factor and clinical symptoms
in medicated patients with major depression. J Affect Disord.
2011;135(1–3):332–5.
16. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al.
Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in
depressed patients with or without antidepressants. Biol Psychiatry.
2003;54(1):70–5.
17. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant
treatment on serum brain-derived neurotrophic factor levels in depressed
patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry.
2005;29(2):261–5.
18. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor,
depression, and antidepressant medications: meta-analyses and
implications. Biol Psychiatry. 2008;64(6):527–32.
19. Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, et al.
Effects of paroxetine or milnacipran on serum brain-derived neurotrophic
factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry.
2007;31(5):1034–7.
20. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of
temperament and character. Arch Gen Psychiatry. 1993;50(12):975–90.
21. Kimura S, Sato T, Takahashi T, Narita T, Hirano S, Goto M. Typus
melancholicus and the Temperament and Character Inventory personality
dimensions in patients with major depression. Psychiatry Clin Neurosci.
2000;54(2):181–9.
22. Kampman O, Poutanen O. Can onset and recovery in depression be
predicted by temperament? A systematic review and meta-analysis. J Affect
Disord. 2011;135(1–3):20–7.
23. Kampman O, Poutanen O, Illi A, Setala-Soikkeli E, Viikki M, Nuolivirta T, et al.
Temperament profiles, major depression, and response to treatment with
SSRIs in psychiatric outpatients. Eur Psychiatry. 2012;27(4):245–9.
24. Hansenne M, Reggers J, Pinto E, Kjiri K, Ajamier A, Ansseau M. Temperament
and character inventory (TCI) and depression. J Psychiatr Res. 1999;33(1):31–6.
25. Kaneda A, Yasui-Furukori N, Nakagami T, Sato Y, Kaneko S. The influence of
personality factors on paroxetine response time in patients with major
depression. J Affect Disord. 2011;135(1–3):321–5.
26. Celikel FC, Kose S, Cumurcu BE, Erkorkmaz U, Sayar K, Borckardt JJ, et al.
Cloninger’s temperament and character dimensions of personality in patients
with major depressive disorder. Compr Psychiatry. 2009;50(6):556–61.
27. Hirano S, Sato T, Narita T, Kusunoki K, Ozaki N, Kimura S, et al. Evaluating the
state dependency of the Temperament and Character Inventory dimensions
in patients with major depression: a methodological contribution. J Affect
Disord. 2002;69(1–3):31–8.
28. Hur JW, Kim YK. Comparison of clinical features and personality dimensions
between patients with major depressive disorder and normal control.
Psychiatry Investig. 2009;6(3):150–5.
29. Cloninger CR, Svrakic DM, Przybeck TR. Can personality assessment predict
future depression? A twelve-month follow-up of 631 subjects. J Affect
Disord. 2006;92(1):35–44.
30. Lang UE, Hellweg R, Gallinat J. BDNF serum concentrations in healthy
volunteers are associated with depression-related personality traits.
Neuropsychopharmacology. 2004;29(4):795–8.
31. Terracciano A, Martin B, Ansari D, Tanaka T, Ferrucci L, Maudsley S, et al.
Plasma BDNF concentration, Val66Met genetic variant and depression-
related personality traits. Genes Brain Behav. 2010;9(5):512–8.
32. Okuno K, Yoshimura R, Ueda N, Ikenouchi-Sugita A, Umene-Nakano W, Hori
H, et al. Relationships between stress, social adaptation, personality traits,
brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol
plasma concentrations in employees at a publishing company in Japan.
Psychiatry Res. 2011;186(2–3):326–32.
33. Minelli A, Zanardini R, Bonvicini C, Sartori R, Pedrini L, Gennarelli M, et al.
BDNF serum levels, but not BDNF Val66Met genotype, are correlated with
personality traits in healthy subjects. Eur Arch Psychiatry Clin Neurosci.
2011;261(5):323–9.
Nomoto et al. BMC Psychiatry Page 5 of 6
34. Yasui-Furukori N, Tsuchimine S, Kaneda A, Sugawara N, Ishioka M, Kaneko S.
Association between plasma brain-derived neurotrophic factor levels
and personality traits in healthy Japanese subjects. Psychiatry Res.
2013;210(1):220–3.
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry.
1960;23:56–62.
36. Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Jpn J Clin
Psychopharmacol. 2006;9(7):1443–7. part 18.
37. Kijima N, Tanaka E, Suzuki N, Higuchi H, Kitamura T. Reliability and validity of
the Japanese version of the Temperament and Character Inventory. Psychol
Rep. 2000;86(3 Pt 1):1050–8.
38. Sato T, Narita T, Hirano S, Kusunoki K, Goto M, Sakado K, et al. Factor validity
of the temperament and character inventory in patients with major
depression. Compr Psychiatry. 2001;42(4):337–41.
39. Terracciano A, Lobina M, Piras MG, Mulas A, Cannas A, Meirelles O, et al.
Neuroticism, depressive symptoms, and serum BDNF. Psychosom Med.
2011;73(8):638–42.
40. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low
brain-derived neurotrophic factor (BDNF) levels in serum of depressed
patients probably results from lowered platelet BDNF release unrelated to
platelet reactivity. Biol Psychiatry. 2005;57(9):1068–72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Nomoto et al. BMC Psychiatry Page 6 of 6
